IC
OTLK icon

IEQ Capital’s Outlook Therapeutics OTLK Stock Holding History

IEQ Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,968
Closed -$17.5K – 2018
2025
Q2 		$17.5K Buy
+10,968
New +$17.5K ﹤0.01% 1796

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEQ Capital's OTLK Position: Q3 2025 in Review

IEQ Capital sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 10,968 shares — an estimated $17.5K sold.

IEQ Capital first reported a position in OTLK in Q2 2025 and held it in 1 quarter. The position peaked at $17.5K in Q2 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • IEQ Capital reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
  • IEQ Capital sold 10,968 Outlook Therapeutics shares in Q3 2025, an estimated $17.5K.
  • IEQ Capital first reported a position in Outlook Therapeutics in Q2 2025 and held it in 1 quarter.
  • IEQ Capital's Outlook Therapeutics position peaked at $17.5K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on IEQ Capital's 13F filing for Q3 2025, filed 14 Nov 2025.